Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Company profile
Ticker
GH
Exchange
Website
CEO
Helmy Eltoukhy
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Guardant Health AMEA, Inc. • Guardant Health Pte. Ltd. • Guardant Health Japan Corp. • Guardant Holdings (Switzerland) GmbH • Bellwether Bio, Inc. • Morpheus Merger Sub, Inc. • Guardant Health Screening Corp. • Guardant Health International, Inc. • Guardant Health UK Limited • Guardant Health Spain S.R.L. ...
IRS number
454139254
GH stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
2 Mar 23
8-K
Musa Tariq joins Guardant Health board of directors
27 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
23 Feb 23
8-K
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
9 Jan 23
8-K
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
15 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Guardant Health Reports Third Quarter 2022 Financial Results
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Transcripts
GH
Earnings call transcript
2022 Q4
23 Feb 23
GH
Earnings call transcript
2022 Q3
4 Nov 22
GH
Earnings call transcript
2022 Q2
5 Aug 22
GH
Earnings call transcript
2022 Q1
6 May 22
GH
Earnings call transcript
2021 Q4
24 Feb 22
GH
Earnings call transcript
2021 Q3
5 Nov 21
GH
Earnings call transcript
2021 Q2
6 Aug 21
GH
Earnings call transcript
2021 Q1
7 May 21
GH
Earnings call transcript
2020 Q4
25 Feb 21
GH
Earnings call transcript
2020 Q3
6 Nov 20
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 141.95 mm | 141.95 mm | 141.95 mm | 141.95 mm | 141.95 mm | 141.95 mm |
| Cash burn (monthly) | 5.55 mm | 29.20 mm | 48.71 mm | 55.03 mm | 30.25 mm | 36.42 mm |
| Cash used (since last report) | 15.09 mm | 79.30 mm | 132.30 mm | 149.46 mm | 82.16 mm | 98.94 mm |
| Cash remaining | 126.86 mm | 62.65 mm | 9.65 mm | -7.52 mm | 59.78 mm | 43.01 mm |
| Runway (months of cash) | 22.8 | 2.1 | 0.2 | -0.1 | 2.0 | 1.2 |
Institutional ownership, Q4 2022
92.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 292 |
| Opened positions | 58 |
| Closed positions | 92 |
| Increased positions | 88 |
| Reduced positions | 98 |
| 13F shares | Current |
|---|---|
| Total value | 2.49 tn |
| Total shares | 95.39 mm |
| Total puts | 472.30 k |
| Total calls | 1.63 mm |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| FMR | 15.31 mm | $416.34 bn |
| Vanguard | 9.04 mm | $245.89 bn |
| Capital International Investors | 7.85 mm | $213.57 bn |
| BLK Blackrock | 5.50 mm | $149.48 bn |
| MS Morgan Stanley | 5.22 mm | $141.86 bn |
| Viking Global Investors | 4.11 mm | $111.73 bn |
| Khosla Ventures IV | 2.67 mm | $208.86 mm |
| Clearbridge Advisors | 2.59 mm | $70.37 bn |
| Alliancebernstein | 2.52 mm | $68.43 bn |
| Credit Suisse | 2.11 mm | $57.42 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Mar 23 | Potter Myrtle S | RSU | Grant | Acquire A | No | No | 0 | 68 | 0.00 | 1,162 |
| 15 Mar 23 | Potter Myrtle S | RSU COMMON STOCK | Option exercise | Dispose M | No | No | 0 | 68 | 0.00 | 2,121 |
| 15 Mar 23 | Michael Brian Bell | COMMON STOCK | Payment of exercise | Dispose F | No | No | 26.78 | 1,703 | 45.61 k | 7,279 |
| 15 Mar 23 | Michael Brian Bell | COMMON STOCK | Option exercise | Acquire M | No | No | 0 | 4,931 | 0.00 | 8,982 |
| 15 Mar 23 | Michael Brian Bell | RSU COMMON STOCK | Option exercise | Dispose M | No | No | 0 | 4,931 | 0.00 | 14,796 |
| 15 Mar 23 | Helmy Eltoukhy | COMMON STOCK | Buy | Acquire P | No | No | 26.1544 | 8,600 | 224.93 k | 2,049,238 |
| 14 Mar 23 | Helmy Eltoukhy | COMMON STOCK | Buy | Acquire P | No | No | 26.3334 | 84,452 | 2.22 mm | 2,040,638 |
| 14 Mar 23 | AmirAli Talasaz | COMMON STOCK | Buy | Acquire P | Yes | No | 26.3972 | 4,250 | 112.19 k | 24,250 |
| 14 Mar 23 | AmirAli Talasaz | COMMON STOCK | Buy | Acquire P | Yes | No | 26.3972 | 4,250 | 112.19 k | 24,250 |
| 14 Mar 23 | AmirAli Talasaz | COMMON STOCK | Buy | Acquire P | No | No | 26.3972 | 8,500 | 224.38 k | 1,902,345 |
News
Guardant Health Earnings Perspective: Return On Capital Employed
16 Mar 23
Stocks That Hit 52-Week Lows On Friday
10 Mar 23
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
9 Mar 23
Sermonix Pharma And Guardant Health Initiated Phase 3 Study Comparing Lasofoxifene Plus Abemaciclib Combo Vs. Fulvestrant Plus Abemaciclib In Pre-And Post-Menopausal Subjects With Locally Advanced Or Metastatic ER+/HER2-Breast Cancer With ESR1 Mutation
9 Mar 23
Citigroup Downgrades Guardant Health to Neutral, Lowers Price Target to $33
9 Mar 23
Press releases
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
21 Mar 23
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
10 Mar 23
Musa Tariq Joins Guardant Health Board of Directors
27 Feb 23
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
23 Feb 23
Guardant Health to Participate in Upcoming March Investor Conferences
17 Feb 23